The purpose of the trial is to evaluate how safe the vaccine is and how well it triggers an immune response. Participants receive the injection at the start of the study and then return for brief check‑ins over the next two weeks to report any reactions such as soreness at the injection site, fever, or other symptoms. Blood samples are taken before the shot and again about two weeks later to measure antibodies, which are proteins the immune system makes to block the virus.

The main aim of the trial is to assess the safety and immune response of the mixed vaccine. Participants receive a single injection and are observed for a short period right after the shot. They then return for follow‑up visits a few weeks later and again several months later to check for any side effects and to see how well the body has responded to the vaccine.

During the study, volunteers are asked to report any local reactions such as soreness at the injection site and systemic symptoms like fever or fatigue. Small blood samples are taken to measure the level of antibodies—proteins that help the immune system recognize and fight the flu virus—and to evaluate other immune cells. Any serious problems that arise are recorded and reviewed throughout the study period.

The purpose of the study is to determine whether the combined vaccine prevents doctor visits or hospital stays caused by flu or COVID‑19 as well as, or better than, the two separate shots. Participants aged 65 years or older will receive either the combined vaccine or the two separate vaccines on the same day and will be observed for several months. Any illness that leads to a medical appointment, emergency care, or hospitalization will be recorded to assess the vaccine’s effectiveness.

The purpose is to see how taking this antibiotic affects the rate of resistant nasal bacteria, the frequency of sexually transmitted infections, and the composition of gut bacteria over one year. Participants will be asked to take the study tablet for about 12 months, attend a few clinic visits for simple nose swabs (samples taken from the inside of the nose) and stool samples, and answer short questionnaires about health and sexual activity. The study will compare the outcomes with those of participants who do not receive the antibiotic.

The purpose of the study is to see whether switching to this injection regimen keeps the virus suppressed as well as continuing the usual oral pills. Participants will receive the injection at the start of the study and then every six months, while regular clinic visits will collect blood samples to check the amount of virus, the number of CD4+ T‑cells (a type of immune cell that helps fight infections), and any changes in health over about two years.

Throughout the trial, safety will be closely watched. Any side effects or problems will be recorded, and participants may stop the study medication if serious issues arise. Blood tests will also measure how much of the new drugs remain in the body and whether the body develops any antibodies against them.

The purpose of the study is to see whether switching to the antibody‑plus‑capsid‑inhibitor regimen keeps the virus suppressed as well as the standard long‑acting injectables. Participants will receive their assigned injections or tablets on a set schedule for about two years, with regular clinic visits to check health, simple blood tests, and any side effects.

After an initial screening, participants start the assigned treatment, receive the first dose in the clinic, and then return at predetermined intervals for repeat doses and basic blood checks. Throughout the study, doctors will watch for common side effects and will measure immune cell numbers to ensure safety.

The purpose of the trial is to determine whether this combination can achieve durable immunological control of the virus when antiretroviral therapy is stopped. After receiving the study infusions, participants will pause their regular ART under close medical supervision and will have regular blood tests to monitor viral levels and immune‑cell counts; if the virus rises above predefined thresholds or immune cells fall, treatment will be restarted.

During the entire study period, participants will be monitored for any side effects or laboratory changes, and any serious problems will be reported to the study team, with follow‑up extending for several months after the therapy interruption.

The purpose is to compare the bioavailability of the liquid suspension with that of the tablet form and to see whether eating food changes how much of the drug reaches the bloodstream.

Healthy volunteers will receive each form of the medicine in separate periods, sometimes on an empty stomach and sometimes after a meal, using a crossover design. Blood samples will be collected to measure the drug levels over time, which is part of a pharmacokinetic assessment, and participants will be monitored for any side effects.

The purpose of the study is to see if this immune modulation approach lowers the amount of virus in the blood compared with keeping the standard drug regimen. Participants will be assigned to one of the two adjustment strategies or to continue their current treatment, and their virus levels will be checked at the start and again after a few weeks. Additional blood tests will look at how the immune system responds to the virus, and the data will help determine whether the new strategies are effective.

The purpose of the study is to determine whether individuals with a favorable genetic and clinical background can maintain low levels of the virus after stopping medication. After an initial treatment period, the medication will be stopped in a process called analytical treatment interruption, and participants will be closely monitored for up to 24 weeks. Blood tests will measure the viral load (the amount of virus in the blood) and will also look at immune cells such as CD4 and CD8 lymphocytes and NK cells; laboratory techniques like flow cytometry and NGS will be used to study these cells and the virus that remains hidden in the body.

Participants are randomly assigned to receive the medicines and are followed for several weeks. They will take the oral tablets for a set number of days and receive the infusion on specific days. Swabs from the nose and throat are collected at multiple time points (for example, day 5, day 15, day 22, and later) and are tested using a laboratory method called PCR to see if viral genetic material is present. The study also records any side effects, serious health problems, and whether treatment is stopped early, with follow‑up visits and sample collections continuing up to about 50 days after treatment begins.

The purpose is to determine whether early vaccination changes how strong the immune protection is later, measured by the amount of neutralising antibodies against measles several years after the routine dose given at age 4. Children are followed for up to three years after that routine dose, and blood samples are tested using a plaque-reduction neutralisation test and also to assess levels of IgG, a protein that shows immune memory. The study follows each child through the early vaccination, the routine dose, and the later check‑ups without requiring special procedures beyond routine clinic visits.

The purpose of the study is to determine whether adding dasatinib can change the number and activity of important immune cells, specifically the white‑blood‑cell types called CD4, CD8 and CD56+. Participants will take either dasatinib or placebo for about a year, with regular clinic visits where blood samples are taken at several intervals (early after starting, then roughly every few months) to measure these cells, inflammation signals, and any side effects. Terms such as “viral reservoir” refer to the hidden virus that remains in cells despite treatment, and “inflammation markers” are blood signals that show how much inflammation is present.

Throughout the trial, doctors will closely watch for any adverse events, meaning any unwanted medical problems, and will perform routine laboratory tests to ensure safety. The study will track how the immune cells and inflammation markers change over time, providing information on whether dasatinib can offer additional benefit to people already on antiretroviral therapy.

The purpose of the research is to compare brain activity and structure, as well as immune‑related blood findings, between people with ongoing symptoms and those who have recovered fully. Participants will have a brief blood draw, undergo a scan that measures cellular energy use using PET, and receive a detailed brain scan with MRI that shows both structure and function. After the imaging sessions, individuals will complete questionnaires about the presence and severity of their symptoms. The study follows a straightforward schedule of these visits over several weeks, without any additional experimental treatments.

The purpose of the study is to evaluate the safety and how well participants tolerate a step‑up dosing schedule of 25 mg, then 50 mg, and finally 100 mg of the drug. Volunteers will take the tablet at each dose level for a short period, after which they will provide saliva samples to check for the amount of virus present and have blood drawn to measure immune responses such as the number of CD4 T cells that react to the virus using a test called ELISPOT, as well as levels of specific antibodies, including IgG. The study proceeds without complex procedures, allowing participants to continue their normal daily activities while being monitored for any side effects.

People in the study are assigned by chance to receive either acetylcysteine or sodium chloride. The treatment is given during the hospital stay, and the study then follows the course of recovery over the next days and months. The study looks at how well participants do after treatment, including survival and length of hospital stay, without using complicated procedures in the description.

Sepsis is a serious reaction to infection that can quickly become life-threatening. Liver dysfunction means the liver is injured or not working normally. The purpose of this study is to assess whether acetylcysteine can help adults with severe infection and liver dysfunction recover better.

In the study, participants receive one booster dose of the vaccine in the muscle. The study then follows how the body responds over the next days after the booster. Blood samples are taken during the study to check for signs of protection, and any side effects such as pain, redness, swelling, headache, fever, or tiredness are recorded. The study compares the three earlier vaccination plans to see which one gives a strong response after the booster.

The study is planned in two parts. In the first part, maribavir is taken for about 6 months. If the virus level drops but does not fall enough, treatment may continue for about 3 more months. During the study, the health of the participants and the amount of virus in the body are followed over time, along with whether the virus comes back after treatment is stopped.

Epstein-Barr virus is a common virus that can stay active in the body after infection. In people who have had a kidney transplant, the immune system is weakened to protect the new organ, and this can make it harder to control the virus. Maribavir is an antiviral medicine, which means it is designed to stop a virus from making more copies of itself.

During the study, participants receive flutemetamol (18F) and then undergo a PET scan, which is an imaging test that shows where the tracer goes in the body. Some participants may also have a MRI scan, which uses magnetic fields to create pictures of the brain. Blood samples and symptom questionnaires are also used to gather more information about the amount of microclots and the presence and severity of symptoms.

The study is expected to run over several months. It focuses on whether this imaging method can show differences in amyloid-containing microclots between people with post-COVID syndrome and controls, and whether these findings relate to symptoms and brain scan results.

The research is divided into two parts. The first part involves a one-day treatment to see how the medications affect the virus within certain cells. The second part involves a four-week treatment to evaluate if the combination of drugs can reduce the overall amount of viral genetic material, known as HIV-DNA, present in the body. Participants may receive the active medications or a placebo.

The purpose is to find out whether a booster given during lactation increases the amount of protective antibodies in breastmilk over three months compared with mothers who do not receive the vaccine. Mothers receive a single injection and then provide breastmilk samples about five times during the three‑month period. Antibodies are proteins that recognize and help neutralize germs, and the humoral immune response refers to this antibody‑based protection. The study also checks the activity of immune cells in the milk.

The main aim of the trial is to find out whether bupropion can reduce the level of fatigue and improve physical functioning in people with this condition. Participants are assigned by chance to receive either the active drug or the placebo, take the study tablets for about eight weeks, and attend a few clinic visits: one at the start, one midway through treatment, one at the end of the eight‑week period, and a follow‑up about four weeks later. During these visits, simple questionnaires and short physical tests are completed.

The questionnaires include the Fatigue Severity Scale, which asks the participant to rate how often they feel exhausted during daily activities, and the Short Form-36 Physical Function, which measures how easy it is to perform common tasks such as walking or climbing stairs. Additional brief surveys evaluate mood, anxiety and breathing difficulty, while a quick sit‑to‑stand test checks basic exercise capacity. All assessments are designed to be easy to understand and complete.

During the study, radiomics will be applied to the images. This is a method that uses computers to extract large amounts of detailed data from medical scans that are not visible to the human eye. These computer-generated details are then analyzed to help distinguish between an actual infection and other types of inflammation. This approach may help in predicting whether an infection is healing, which could eventually help in deciding when it is safe to stop using long-term antimicrobial therapy, which is medication used to fight bacteria.

The purpose of this study is to assess the safety and tolerability of single and multiple doses of the study drug. During the course of the research, participants will receive the treatment to observe how the body processes the substances and how it affects various markers of the virus. Researchers will monitor levels of HBsAg, which is a protein on the surface of the virus, and HBV DNA, which is the genetic material of the virus, to see if the treatment helps reduce the presence of the infection.

The goal of the study is to evaluate how well the experimental treatment controls the HIV-1 RNA, which is a measure of the amount of virus in the blood. The research also aims to monitor the safety and how well the body tolerates the medications over time. During the course of the study, participants will be observed for a set period to track changes in their viral levels and their CD4+ T-cell count, which is a type of white blood cell that helps the body fight infections.

The study is divided into two stages. In the first stage, the effectiveness and safety of the weekly treatment are assessed in an open manner. In the second stage, a more controlled method is used where neither the participants nor the researchers know which specific treatment is being administered to ensure unbiased results. Participants will be monitored through various stages of the study to collect data on how the virus responds to the treatment and to identify any potential side effects.

During the study, the effects of these treatments will be observed across various areas of health, such as fatigue, breathing, memory, thinking, communication, muscles, joints, and circulation. The course of the study involves monitoring changes in these symptoms over time. Additionally, researchers will look at blood biomarkers, which are natural substances found in the blood that can indicate how the body is functioning, as well as plasma proteomics and plasma metabolomics, which are specialized tests used to study proteins and metabolites to understand the biological processes occurring in the body.

During the study, participants will take multiple doses of nirmatrelvir/ritonavir. After these doses, a single oral dose of rosuvastatin will be administered. Researchers will then monitor the pharmacokinetics, which refers to how a drug moves through the body, including how it is absorbed, distributed, and eliminated. This process is measured by looking at the concentration of the medicine in the blood over time.

The study involves healthy participants aged 16 to 40 years. Participants will receive the mRNA-1647 vaccine or a placebo through a series of three injections. The trial will monitor participants over a period of time to see if the vaccine can prevent CMV infection and to check for any side effects. The study will also involve the use of Sodium Chloride 0.9%, which is a common solution used in medical settings, as part of the injection process.

The main goal of the study is to demonstrate the effectiveness of the mRNA-1647 vaccine in preventing CMV infection in participants who have not been previously exposed to the virus. The trial will also assess the safety of the vaccine and how well it is tolerated by participants. This research is important for developing new ways to protect people from CMV and improve public health outcomes.

Participants will take different liquid versions of the study medicine in a single-blind format, meaning they will not know which specific version they are receiving. During the study, various liquid bases will be used to create a suspension, which is a mixture where solid particles are dispersed throughout a liquid. The experience will be assessed based on sensations such as bitterness, sweetness, sourness, saltiness, the feeling in the mouth, and any burning sensations on the tongue.

Patients in this study will be adults admitted to the hospital with suspected infection who show signs that their organs are not working properly. They must have been admitted within 72 hours with an infection that doctors expect will require hospital care for more than 24 hours. The study will compare patients who receive individualized treatment based on their specific medical problems against those who receive standard care. The treatments may be given alone or in combination depending on what each patient needs, and the treatment period can last up to 8 days for some medications and 1 day for others.

During the study, doctors will monitor patients closely for any side effects and will track how many days patients are alive and out of the hospital at 14 days and 30 days after joining the study. They will also measure other important outcomes such as survival rates at different time points, whether patients need intensive care, how long they stay in the hospital, their quality of life after six months, and whether they need additional treatments such as breathing support, blood pressure medications, or blood transfusions. The study will also track how long patients need antibiotics and whether their antibiotic treatment needs to be changed or increased.

During the study, some people will receive brelovitug while others will have their treatment delayed. All people taking part will also need to take one of the following medicines for hepatitis B: tenofovir disoproxil fumarate, tenofovir alafenamide fumarate, or entecavir. The study will measure whether the virus levels in the blood decrease by a certain amount or become undetectable, and whether liver enzyme levels return to normal. Liver enzyme is a substance in the blood that shows how well the liver is working, and when it is high, it can mean the liver is inflamed or damaged.

The study will also look at the safety of the treatment by checking for any unwanted effects and how many people need to stop treatment because of these effects. Other measurements will include checking liver stiffness, which shows how much scarring has occurred in the liver, and various scores that help doctors understand how well the liver is functioning. These checks will happen at different times during the study, including at weeks 24, 48, and 96 of treatment. The study is expected to last until early 2028.

Participants entering this study must already be taking bulevirtide for at least 6 months for their chronic hepatitis D infection. They will also need to be taking one of the following medications for hepatitis B and continue taking it throughout the study: TDF, TAF, or ETV. During the study, participants will switch from their current bulevirtide treatment to receiving BJT-778 injections under the skin. The study will measure how many participants have the hepatitis D virus become undetectable in their blood after switching to the new treatment.

The study will also look at safety by tracking any unwanted effects that occur during treatment, how many participants stop treatment because of unwanted effects, and changes in bile salts in the blood. Other measurements will include how many participants have their virus levels drop significantly or become undetectable at different time points, whether liver enzyme levels called ALT return to normal, and whether the virus remains undetectable after treatment ends. The treatment period can last up to 96 weeks, with additional follow-up visits after treatment is completed.

The purpose of the study is to find out if the Arexvy vaccine can strengthen the body’s natural defense system in people with lung disease who are at higher risk for severe breathing infections. The researchers want to see if giving Arexvy can help the body respond better to the Prevenar 20 vaccine when they are given at the same time or close together. They will also look at whether Arexvy provides broader protection against various breathing infections and helps control viruses that may stay in the body for a long time.

Participants in this study will receive injections of the vaccines in their arm muscle. Some people will get both vaccines at the same time, while others will receive them at different times. The study will involve blood sample collections at different time points to measure how well the immune system, which is the body’s defense against infections, responds to the vaccines. The researchers will look at specific markers in the blood that show how active the immune system is and measure the levels of protective proteins called antibodies that the body makes after vaccination. The study will follow participants for several months after they receive the vaccines to see how long the protection lasts.

The purpose of the study is to find out if adding Privigen to standard care helps patients recover from COVID-19 better than standard care alone. The study will specifically look at whether patients recover clinically and whether the virus is cleared from their blood by day 28 after joining the study. Patients in this study will have had COVID-19 symptoms for at least 7 days, will have received full COVID-19 vaccination, and will have the virus present in their blood. They will also have very low levels of antibodies against the virus due to their weakened immune system caused by their disease or treatment.

During the study, patients will be randomly assigned to receive either Privigen added to their standard care or standard care alone. The study will track how well patients are doing using a scale that measures their clinical condition, and will check whether the virus can still be found in their blood at different time points. The study will follow patients for several months to see if they maintain their recovery and to monitor for any side effects or safety concerns related to the treatments.